Sign In
Buy DOCS
$21.04
-0.470 (-2.19%)
At Close: Jun 03, 2026
Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers
04:05pm, Thursday, 07'th Aug 2025
Doximity has acquired the AI startup Pathway Medical for $63 million. Pathway has one of the largest structured datasets in medicine, Doximity said.
Doximity Announces Fiscal 2026 First Quarter Financial Results
04:01pm, Thursday, 07'th Aug 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025.
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
03:29pm, Sunday, 03'rd Aug 2025
It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Thursday, 31'st Jul 2025
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures
05:00am, Thursday, 31'st Jul 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2025 Physician Compensation Report. The findings highlight
OMCL vs. DOCS: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 30'th Jul 2025
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS). But which of these two stocks offers value investors a better bang for their
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note
07:16pm, Tuesday, 29'th Jul 2025
In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.
Doximity: Slowing Sales And EBITDA Growth
03:35pm, Wednesday, 23'rd Jul 2025
Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased in
Doximity (DOCS) Upgraded to Strong Buy: Here's Why
01:01pm, Wednesday, 23'rd Jul 2025
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Doximity (DOCS) Stock Drops Despite Market Gains: Important Facts to Note
07:15pm, Tuesday, 22'nd Jul 2025
In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.
Doximity to Release Fiscal 2026 First Quarter Results on August 7, 2025
04:01pm, Thursday, 17'th Jul 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter e
Doximity (DOCS) Rises Higher Than Market: Key Facts
07:16pm, Monday, 14'th Jul 2025
Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.
Dr Martens tiptoes higher after positive America retail trading, UK still challenging
04:06am, Thursday, 10'th Jul 2025
Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weigh
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certai
Doximity Crushes The Rule Of 40 - Try Rule Of 58
10:36am, Wednesday, 02'nd Jul 2025
I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation s
